Oral contraceptives and breast disease.
Eur J Gynaecol Oncol
; 2(3): 105-7, 1981.
Article
en En
| MEDLINE
| ID: mdl-7347679
ABSTRACT
PIP The influence of oral contraceptives (OCs) on breast disease can vary according to their pharmacologic content and interaction with the patient's endocrine habits. Data on this topic are taken from 1) histologic examinations on patients undergoing contraceptive treatment, 2) studies on experimental toxicity in animals, and 3) epidemiologic examinations. The tests have thus far failed to prove that the administration of OCs causes breast cancer or influences the experimental carcinogenesis in primates or sub-primates. Many epidemiologic studies have even shown a decreased risk of mastopathy in contraceptive users. Not only the doses and hormonal content but also the duration of administration, and any simultaneous or subsequent estrogen administration must be considered when evaluating risk. Combinations of OCs with estrogen predominance must be avoided in patients affected by mastosis.^ieng
Palabras clave
Breast Cancer; Cancer; Contraception; Contraceptive Agents, Estrogen; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin; Contraceptive Agents--side effects; Contraceptive Methods--side effects; Diseases; Estradiol; Estriol; Estrogens; Estrone; Family Planning; Neoplasms; Oral Contraceptives--side effects; Reproductive Control Agents--side effects
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Enfermedades de la Mama
/
Neoplasias de la Mama
/
Anticonceptivos Orales
/
Enfermedad Fibroquística de la Mama
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
Idioma:
En
Año:
1981
Tipo del documento:
Article